227 related articles for article (PubMed ID: 27987561)
1. Imaging in Central Nervous System Drug Discovery.
Gunn RN; Rabiner EA
Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
[TBL] [Abstract][Full Text] [Related]
2. Translational PET imaging research.
Hargreaves RJ; Rabiner EA
Neurobiol Dis; 2014 Jan; 61():32-8. PubMed ID: 24055214
[TBL] [Abstract][Full Text] [Related]
3. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD
Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
[TBL] [Abstract][Full Text] [Related]
4. Modeling of PET data in CNS drug discovery and development.
Varnäs K; Varrone A; Farde L
J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography in CNS drug discovery and drug monitoring.
Piel M; Vernaleken I; Rösch F
J Med Chem; 2014 Nov; 57(22):9232-58. PubMed ID: 25144329
[TBL] [Abstract][Full Text] [Related]
6. The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.
Safavi M; Sabourian R; Abdollahi M
Expert Opin Drug Discov; 2016 Oct; 11(10):939-56. PubMed ID: 27454411
[TBL] [Abstract][Full Text] [Related]
7. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
Cole PE; Schwarz AJ; Schmidt ME
Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
[TBL] [Abstract][Full Text] [Related]
8. The role of imaging in proof of concept for CNS drug discovery and development.
Wong DF; Tauscher J; Gründer G
Neuropsychopharmacology; 2009 Jan; 34(1):187-203. PubMed ID: 18843264
[TBL] [Abstract][Full Text] [Related]
9. PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?
Barrett JS; McGuire J; Vezina H; Spitsin S; Douglas SD
J Clin Psychopharmacol; 2013 Dec; 33(6):725-8. PubMed ID: 24100788
[TBL] [Abstract][Full Text] [Related]
10. The value of PET ligand discovery to CNS drug development.
Schmidt ME; Andrés JI
Future Med Chem; 2017 Mar; 9(4):351-356. PubMed ID: 28263084
[No Abstract] [Full Text] [Related]
11. Positron emission tomographic imaging in drug discovery.
Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
[TBL] [Abstract][Full Text] [Related]
12. The application of positron emission tomography (PET) imaging in CNS drug development.
Suridjan I; Comley RA; Rabiner EA
Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Central Nervous System Drug Development Using Molecular Imaging.
Hargreaves RJ; Hoppin J; Sevigny J; Patel S; Chiao P; Klimas M; Verma A
Clin Pharmacol Ther; 2015 Jul; 98(1):47-60. PubMed ID: 25869938
[TBL] [Abstract][Full Text] [Related]
14. Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.
Suhara T; Chaki S; Kimura H; Furusawa M; Matsumoto M; Ogura H; Negishi T; Saijo T; Higuchi M; Omura T; Watanabe R; Miyoshi S; Nakatani N; Yamamoto N; Liou SY; Takado Y; Maeda J; Okamoto Y; Okubo Y; Yamada M; Ito H; Walton NM; Yamawaki S
Int J Neuropsychopharmacol; 2017 Apr; 20(4):285-294. PubMed ID: 28031269
[TBL] [Abstract][Full Text] [Related]
15. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
Rossi T; Braggio S
Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
[TBL] [Abstract][Full Text] [Related]
16. What is the value of human FMRI in CNS drug development?
Wise RG; Preston C
Drug Discov Today; 2010 Nov; 15(21-22):973-80. PubMed ID: 20813202
[TBL] [Abstract][Full Text] [Related]
17. Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.
de Lange ECM; van den Brink W; Yamamoto Y; de Witte WEA; Wong YC
Expert Opin Drug Discov; 2017 Dec; 12(12):1207-1218. PubMed ID: 28933618
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of CNS drugs with PET].
Takano A
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943
[TBL] [Abstract][Full Text] [Related]
19. Antibody positron emission tomography imaging in anticancer drug development.
Lamberts LE; Williams SP; Terwisscha van Scheltinga AG; Lub-de Hooge MN; Schröder CP; Gietema JA; Brouwers AH; de Vries EG
J Clin Oncol; 2015 May; 33(13):1491-504. PubMed ID: 25779566
[TBL] [Abstract][Full Text] [Related]
20. CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson PH; Clark JA; Cross AJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():171-187. PubMed ID: 27575715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
